1
|
Rubery MS, Ose N, Schneider M, Moore AS, Carrera J, Mariscal E, Ayers J, Bell P, Mackinnon A, Bradley D, Landen OL, Thompson N, Carpenter A, Winters S, Ehrlich B, Sarginson T, Rendon A, Liebman J, Johnson K, Merril D, Grant G, Shingleton N, Taylor A, Ruchonnet G, Stanley J, Cohen M, Kohut T, Issavi R, Norris J, Wright J, Stevers J, Masters N, Latray D, Kilkenny J, Stolte WC, Conlon CS, Troussel P, Villette B, Emprin B, Wrobel R, Lejars A, Chaleil A, Bridou F, Delmotte F. A 2-4 keV multilayer mirrored channel for the NIF Dante system. Rev Sci Instrum 2022; 93:113502. [PMID: 36461505 DOI: 10.1063/5.0101695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 09/09/2022] [Indexed: 06/17/2023]
Abstract
During inertial confinement fusion experiments at the National Ignition Facility (NIF), a capsule filled with deuterium and tritium (DT) gas, surrounded by a DT ice layer and a high-density carbon ablator, is driven to the temperature and densities required to initiate fusion. In the indirect method, 2 MJ of NIF laser light heats the inside of a gold hohlraum to a radiation temperature of 300 eV; thermal x rays from the hohlraum interior couple to the capsule and create a central hotspot at tens of millions degrees Kelvin and a density of 100-200 g/cm3. During the laser interaction with the gold wall, m-band x rays are produced at ∼2.5 keV; these can penetrate into the capsule and preheat the ablator and DT fuel. Preheat can impact instability growth rates in the ablation front and at the fuel-ablator interface. Monitoring the hohlraum x-ray spectrum throughout the implosion is, therefore, critical; for this purpose, a Multilayer Mirror (MLM) with flat response in the 2-4 keV range has been installed in the NIF 37° Dante calorimeter. Precision engineering and x-ray calibration of components mean the channel will report 2-4 keV spectral power with an uncertainty of ±8.7%.
Collapse
Affiliation(s)
- M S Rubery
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - N Ose
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - M Schneider
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - A S Moore
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Carrera
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - E Mariscal
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Ayers
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - P Bell
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - A Mackinnon
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - D Bradley
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - N Thompson
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - A Carpenter
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - S Winters
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - B Ehrlich
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - T Sarginson
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - A Rendon
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Liebman
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - K Johnson
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - D Merril
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - G Grant
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - N Shingleton
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - A Taylor
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - G Ruchonnet
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Stanley
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - M Cohen
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - T Kohut
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - R Issavi
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Norris
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Wright
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Stevers
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - N Masters
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - D Latray
- Lawrence Livermore National Laboratory, P. O. Box 808, Livermore, California 94551-0808, USA
| | - J Kilkenny
- General Atomics, San Diego, California 92121, USA
| | - W C Stolte
- MSTS, Mission Support and Test Services LLC, Livermore, California 94550-9239, USA
| | - C S Conlon
- MSTS, Mission Support and Test Services LLC, Livermore, California 94550-9239, USA
| | - Ph Troussel
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - B Villette
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - B Emprin
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - R Wrobel
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - A Lejars
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - A Chaleil
- Commissariat à l'Énergie Atomique (CEA), DAM, DIF, F-91297 Arpajon, France
| | - F Bridou
- Laboratoire Charles Fabry, 2, Av. Augustin Fresnel, 91127 Palaiseau Cedex, France
| | - F Delmotte
- Laboratoire Charles Fabry, 2, Av. Augustin Fresnel, 91127 Palaiseau Cedex, France
| |
Collapse
|
2
|
|
3
|
Buisset J, Olivier J, Villers A, Norris J, Puech P, Drumez E. Évaluation rétrospective de l’incidence du cancer de prostate cliniquement significatif a 10 ans et intérêt de l’utilisation de la densité du PSA dans le choix des premières biopsies en cas d’IRM négative. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Cutler R, Gleeson B, Page S, Norris J, Browning G. Antimicrobial prescribing guidelines for pigs. Aust Vet J 2020; 98:105-134. [PMID: 32281105 DOI: 10.1111/avj.12940] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 08/19/2019] [Accepted: 09/05/2019] [Indexed: 01/16/2023]
|
5
|
Stavrinides V, Norris J, Bott S, Brown L, Burns-Cox N, Dudderidge T, El-Shater Bosaily A, Frangou E, Freeman A, Ghei M, Henderson A, Hindley R, Kaplan R, Kirkham A, Oldroyd R, Parker C, Persad R, Punwani S, Rosario D, Shergill I, Carmona L, Winkler M, Whitaker H, Ahmed H, Emberton M. MRI index lesions in the cancerous prostate: How do they differ from false positive phenotypes? Lessons from the PROMIS study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33748-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
6
|
Norris J, Simpson B, Parry M, Allen C, Ball R, Freeman A, Kelly D, Kim H, Kirkham A, You S, Kasivisvanathan V, Whitaker H, Emberton M. mpMRI-visible prostate cancer is enriched with genomic hallmarks of poor prognosis: A bioinformatic analysis. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33723-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Norris J, Carmona Echeverria L, Bott S, Brown L, Burns-Cox N, Dudderidge T, El-Shater Bosaily A, Frangou E, Freeman A, Ghei M, Henderson A, Hindley R, Kaplan R, Kirkham A, Oldroyd R, Parker C, Persad R, Punwani S, Rosario D, Shergill I, Stavrinides V, Winkler M, Whitaker H, Ahmed H, Emberton M. Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32877-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Polinski K, Bemis E, Demoruelle K, Seifert J, Crume T, Yang F, Robinson W, Clare-Salzler M, Deane K, Holers M, Norris J. SAT0596 ASSOCIATIONS BETWEEN CIRCULATING LIPID MEDIATORS AND INCIDENT INFLAMMATORY ARTHRITIS IN AN ANTI-CITRULLINATED PROTEIN ANTIBODY POSITIVE POPULATION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving inflammation in the body (1). Epidemiological studies have shown higher omega-3 PUFA status to be associated with a lower risk of both autoimmunity and progression to inflammatory arthritis (IA) (2,3).Objectives:To determine the association of lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA).Methods:We conducted a prospective cohort study using data from the Studies of the Etiologies of Rheumatoid Arthritis (SERA). SERA enrolled first-degree relatives (FDRs) of individuals with RA (FDR cohort) and individuals who screened positive for RA-related autoantibodies at health fairs (screened cohort). We followed 133 anti-CCP3.1 positive participants, of which 29 developed IA (22 classified as RA by 2010 ACR/EULAR criteria). We quantified lipid mediators from stored plasma samples via liquid chromatography tandem mass spectrometry methods validated against the collection and storage methods used in the study. A priori, we selected 5S-HETE, 15S-HETE and 17S-HDHA because they are precursors to leukotrienes, Lipoxin A4 and Resolvin D series lipid mediators, respectively. We fit Cox proportional hazard models for each lipid mediator as a time-varying covariate. For lipid mediators significantly associated with progression to IA we then examined IL-1β, IL-6, IL-8 and TNF-α (Bio-Plex Pro™ assay) as potential mediators of this relationship.Results:Higher plasma 5S-HETE levels were associated with an increased risk of incident IA after adjusting for age at baseline, cohort (FDR or screened), and shared epitope (SE) status (Table 1). The models examining 15S-HETE and 17S-HDHA had the same trend but did not reach statistical significance. We did not find evidence that the association between 5S-HETE and IA risk was mediated by the tested pro-inflammatory cytokines, suggesting a direct role for this lipid mediator in conversion to IA.Table 1.Hazard ratios and 95% confidence intervals of lipid mediator concentrations associated with IA, n=29 IA casesLipid mediatorCrudeAdjustedb5S-HETE2.10 (1.12, 3.92)2.41 (1.43, 4.07)15S-HETE1.61 (0.88, 2.93)1.52 (0.87, 2.65)17-HDHAa1.59 (0.68, 3.74)1.61 (0.72, 3.56)adichotomized as <limit of detection (reference) or detectedbAdjusted for SE, age at baseline and cohortConclusion:In a prospective cohort of anti-CCP positive individuals, higher circulating levels of 5S-HETE, an important precursor to pro-inflammatory leukotrienes, was associated with subsequent IA. Our findings highlight the potential pathologic and prognostic significance of these PUFA metabolites in inflammatory processes in pre-RA populations.References:[1]Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101.[2]Gan RW, Bemis EA, Demoruelle MK, Striebich CC, Brake S, Feser ML, et al. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology. 2017.[3]Gan RW, Young KA, Zerbe GO, Demoruelle MK, Weisman MH, Buckner JH, et al. Lower omega-3 fatty acids are associated with the presence of anti-cyclic citrullinated peptide autoantibodies in a population at risk for future rheumatoid arthritis: a nested case-control study. Rheumatology. 2016;55(2):367-76.Disclosure of Interests:Kristen Polinski: None declared, Elizabeth Bemis: None declared, Kristen Demoruelle Grant/research support from: Pfizer, Jennifer Seifert: None declared, Tessa Crume: None declared, Fan Yang: None declared, William Robinson: None declared, Michael Clare-Salzler: None declared, Kevin Deane Grant/research support from: Janssen, Consultant of: Inova, ThermoFisher, Janseen, BMS and Microdrop, Michael Holers Shareholder of: AdMIRx, Grant/research support from: AdMIRx, Pfizer, Janssen R&D, Consultant of: AdMIRx, Janssen R&D, Celgene, Bristol-Myers Squibb, Jill Norris Grant/research support from: Janssen R&D, Pfizer, Consultant of: Celgene, BMS
Collapse
|
9
|
Markus H, Levi C, King A, Madigan J, Norris J. Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results. J Vasc Surg 2019. [DOI: 10.1016/j.jvs.2019.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Korpal M, Puyang X, Furman C, Zheng GZ, Banka D, Wu J, Zhang Z, Thomas M, Mackenzie C, Yao H, Rimkunas V, Kumar P, Caleb B, Karr C, Subramanian V, Irwin S, Larsen N, Vaillancourt F, Nguyen TV, Davis A, Chan B, Hao MH, O'Shea M, Prajapati S, Agoulnik S, Kuznetsov G, Kumar N, Yu Y, Lai G, Hart A, Eckley S, Fekkes P, Bowser T, Joshi JJ, Selvaraj A, Wardell S, Norris J, Smith S, Reynolds D, Mitchell L, Wang J, Yu L, Kim A, Rioux N, Sahmoud T, Warmuth M, Smith PG, Zhu P. Abstract P1-10-08: Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-10-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mutations in estrogen receptor alpha (ERα) are detected in up to 30% of breast cancer patients who have relapsed during endocrine therapy. ERα mutations functionally confer resistance to existing classes of endocrine therapies, likely through gaining constitutive activity. The fact that current ER-directed therapies are only partially effective in the ERα mutant setting, and that a significant proportion of resistant breast cancer metastases continue to remain dependent on ERα signaling for growth/survival, highlights the critical need to develop the next generation of ERα antagonists that can overcome aberrant ERα activity. Using structure-based drug design approaches we have identified a novel class of ERα antagonist referred to as Selective ERα Covalent Antagonist (SERCA) that inactivate both wild-type and mutant ERα by targeting a unique cysteine residue that is not conserved among other steroid hormone receptors. Biophysical, biochemical and cellular analyses confirm the covalent mechanism of action, specific binding to ER and selective inhibition of ERα-dependent transcription of SERCAs. H3B-6545 is a highly selective SERCA that potently antagonizes wild-type and mutant ERα in biochemical and cell based assays demonstrating increased potency over standard of care and other experimental agents. In vivo, H3B-6545 shows superior efficacy to fulvestrant in the MCF-7 xenograft model with once daily oral dosing, achieving maximal antitumor activity at doses >10x below the maximum tolerated dose in mice. In addition, H3B-6545 shows superior antitumor activity to both tamoxifen and fulvestrant in patient derived xenograft models of breast cancer carrying estrogen receptor mutations. In summary, H3B-6545 is a first-in-class, orally available and selective ER covalent antagonist with a compelling pre-clinical profile that is being developed for the treatment of ERα positive breast cancer.
Citation Format: Korpal M, Puyang X, Furman C, Zheng GZ, Banka D, Wu J, Zhang Z, Thomas M, Mackenzie C, Yao H, Rimkunas V, Kumar P, Caleb B, Karr C, Subramanian V, Irwin S, Larsen N, Vaillancourt F, Nguyen T-V, Davis A, Chan B, Hao MH, O'Shea M, Prajapati S, Agoulnik S, Kuznetsov G, Kumar N, Yu Y, Lai G, Hart A, Eckley S, Fekkes P, Bowser T, Joshi JJ, Selvaraj A, Wardell S, Norris J, Smith S, Reynolds D, Mitchell L, Wang J, Yu L, Kim A, Rioux N, Sahmoud T, Warmuth M, Smith PG, Zhu P. Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-10-08.
Collapse
Affiliation(s)
- M Korpal
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - X Puyang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Furman
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - GZ Zheng
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - D Banka
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Wu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - Z Zhang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M Thomas
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Mackenzie
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - H Yao
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - V Rimkunas
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Kumar
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - B Caleb
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - C Karr
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - V Subramanian
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Irwin
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Larsen
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - F Vaillancourt
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T-V Nguyen
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Davis
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - B Chan
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - MH Hao
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M O'Shea
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Prajapati
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Agoulnik
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - G Kuznetsov
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Kumar
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - Y Yu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - G Lai
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Hart
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Eckley
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Fekkes
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T Bowser
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - JJ Joshi
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Selvaraj
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Wardell
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Norris
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - S Smith
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - D Reynolds
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - L Mitchell
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - J Wang
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - L Yu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - A Kim
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - N Rioux
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - T Sahmoud
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - M Warmuth
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - PG Smith
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| | - P Zhu
- H3 Biomedicine, Inc., 300 Technology Square, Cambridge, MA; Eisai Inc., 4 Corporate Drive, Andover, MA; Duke University, Research Drive, LSRC Bldg, C251, Durham, NC
| |
Collapse
|
11
|
Klimach S, Gabriel J, Norris J. Should N-acetyl cysteine be given to high risk renal patients prior to contrast CT in the acute setting? Int J Surg 2015. [DOI: 10.1016/j.ijsu.2015.07.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Senaratne N, Norris J. Bladder versus enteric drainage following pancreas transplantation. Int J Surg 2015. [DOI: 10.1016/j.ijsu.2015.07.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Kalantzis G, Norris JH, El-Hindy N, Koukkoulli A, Chengot P, Chang BYP. Oncocytic adenocarcinoma of the lacrimal gland: an unusual presentation. Eye (Lond) 2012; 27:104-5. [PMID: 23174753 DOI: 10.1038/eye.2012.200] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
14
|
O' Reilly P, Ross J, Norris J, Malhotra R. A comparison of facial muscle squeezing versus non-facial muscle squeezing on the efficacy of botulinumtoxin-A injections for the treatment of facial dystonia. Orbit 2012; 31:400-3. [PMID: 23061606 DOI: 10.3109/01676830.2012.711885] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND This study was performed to address whether voluntary muscle squeezing post botulinum toxin-A treatment with increased neuronal activity translates into noticeable patient benefit in practice. METHODS This was a prospective, consecutive, double crossover interventional study. Participants were receiving regular (3 monthly) botulinum toxin-A treatment for aberrant facial nerve regeneration (AFNR), benign essential blepharospasm (BEB) or hemifacial spasm (HFS). Twenty-six participants were recruited and these were randomised into two groups (A and B). Group A performed a program of intensive facial exercises for 5 minutes after their first and third treatment whereas after their second treatment, they were asked to rest in a seated position for 5 minutes, and instructed not to talk or perform any voluntary movements of their face. Conversely group B were only asked to perform squeezing exercises after their second treatment. Outcomes were evaluated objectively using video-recordings and subjectively by questionnaire and telephone interview of participants. RESULTS Video-recording data was complete for 21 participants. There was a mean 40% reduction in the frequency of facial muscle spasms and a 33% lower severity score (video-recordings graded by 1 masked investigator) where intensive facial exercises were performed post-treatment. These findings did not reach statistical significance (Mann- Whitney two-tailed test; p = 0.367). CONCLUSION Although statistical significance was not achievable, this study suggested a possible trend towards an increased efficacy of botulinum toxin-A, with facial muscle squeezing post BTX treatment. Future studies with a larger number and a better defined subset of subjects may lead to statistical significance.
Collapse
Affiliation(s)
- P O' Reilly
- Queen Victoria Hospital, East Grinstead, West Sussex, UK.
| | | | | | | |
Collapse
|
15
|
Kennedy F, Lanfranconi S, Hicks C, Reid J, Gompertz P, Price C, Kerry S, Norris J, Markus HS. Antiplatelets vs anticoagulation for dissection: CADISS nonrandomized arm and meta-analysis. Neurology 2012; 79:686-9. [DOI: 10.1212/wnl.0b013e318264e36b] [Citation(s) in RCA: 136] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
16
|
Norris JH, McCulloch PG. Re: The use of propranolol in the management of periocular capillary haemangioma--a systematic review. Eye (Lond) 2012; 26:1275-6; author reply 1276. [PMID: 22791085 DOI: 10.1038/eye.2012.114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
|
17
|
Abstract
AIMS Prescribing for athletes requires an up-to-date knowledge of the World Anti-Doping Agency's list of prohibited substances. As the London 2012 Olympic Games attract athletes from around the world, we review the current guidelines with respect to all medications licensed for ophthalmic use in the United Kingdom. We describe the process that an ophthalmologist can use to check for permissible medications and also highlight treatments that are contraindicated. METHODS We systematically reviewed all 77 drugs listed in Section 11 of the British National Formulary (Issue 63) for use in the treatment of ophthalmic conditions, and referenced these against the 2012 Prohibited List published by the World Anti-Doping Agency. RESULTS The majority of ophthalmic preparations are suitable for use in- and out-of-competition. Some preparations, such as glucocorticoids, are prohibited when administered systemically but permitted for topical administration. Beta-blockers are prohibited in-competition and oral carbonic anhydrase inhibitors are prohibited in- and out-of competition. CONCLUSION The 2012 Prohibited List has important implications for the pharmacological treatment of ophthalmic conditions in athletes. Clinicians prescribing for athletes have a duty to familiarize themselves with the list in order to avoid causing significant damage to their patient's career and reputation.
Collapse
Affiliation(s)
- R G H Nicholson
- Department of Ophthalmology, Oxford Eye Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
| | | | | | | |
Collapse
|
18
|
Berrian AM, O'Keeffe J, White PW, Norris J, Litt J, More SJ, Olea-Popelka FJ. Risk of bovine tuberculosis for cattle sold out from herds during 2005 in Ireland. Vet Rec 2012; 170:620. [DOI: 10.1136/vr.100674] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- A. M. Berrian
- College of Veterinary Medicine and Biomedical Sciences; Colorado State University; Fort Collins CO USA
| | - J. O'Keeffe
- Centre of Veterinary Epidemiology and Risk Analysis; UCD School of Veterinary Medicine; University College Dublin, Belfield; Ireland
- the Department of Agriculture, Food and the Marine; Dublin Ireland
| | - P. W. White
- Centre of Veterinary Epidemiology and Risk Analysis; UCD School of Veterinary Medicine; University College Dublin, Belfield; Ireland
| | - J. Norris
- Colorado School of Public Health; University of Colorado; Denver CO USA
| | - J. Litt
- Colorado School of Public Health; University of Colorado; Denver CO USA
| | - S. J. More
- Centre of Veterinary Epidemiology and Risk Analysis; UCD School of Veterinary Medicine; University College Dublin, Belfield; Ireland
| | - F. J. Olea-Popelka
- College of Veterinary Medicine and Biomedical Sciences; Colorado State University; Fort Collins CO USA
| |
Collapse
|
19
|
Hettige S, Norris J. Complications of the Transnasal Transsphenoidal Approach to Sellar Tumors: A Single Institution's 5-Year Experience and Review of the Literature. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Gazda GM, Bretcher B, Kissiah W, Kuckleburg R, Lackey H, Lackey H, Norris J, Saylor J, Seidenschnur P, Steele R. Recommended Changes and Additions to APGA Code of Ethics to Accommodate Group Workers. Counselor Education and Supervision 2011. [DOI: 10.1002/j.1556-6978.1973.tb01602.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
21
|
|
22
|
Bowron DT, Soper AK, Jones K, Ansell S, Birch S, Norris J, Perrott L, Riedel D, Rhodes NJ, Wakefield SR, Botti A, Ricci MA, Grazzi F, Zoppi M. NIMROD: The Near and InterMediate Range Order Diffractometer of the ISIS second target station. Rev Sci Instrum 2010; 81:033905. [PMID: 20370190 DOI: 10.1063/1.3331655] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
NIMROD is the Near and InterMediate Range Order Diffractometer of the ISIS second target station. Its design is optimized for structural studies of disordered materials and liquids on a continuous length scale that extends from the atomic, upward of 30 nm, while maintaining subatomic distance resolution. This capability is achieved by matching a low and wider angle array of high efficiency neutron scintillation detectors to the broad band-pass radiation delivered by a hybrid liquid water and liquid hydrogen neutron moderator assembly. The capabilities of the instrument bridge the gap between conventional small angle neutron scattering and wide angle diffraction through the use of a common calibration procedure for the entire length scale. This allows the instrument to obtain information on nanoscale systems and processes that are quantitatively linked to the local atomic and molecular order of the materials under investigation.
Collapse
Affiliation(s)
- D T Bowron
- ISIS Facility, Rutherford Appleton Laboratory, Chilton, Didcot, Oxon OX11 0QX, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Norris JH, Gale RP, Nkumbe H, Backhouse OC, Bernadin P, Chang BY. Oculoplastic surgery in Madagascar: a review. Community Eye Health 2009; 22:S3-4. [PMID: 19888361 PMCID: PMC2767128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- JH Norris
- St James's University Hospital, Leeds, UK
| | - RP Gale
- York District Hospital, York, UK
| | - H Nkumbe
- Andranmadio Hospital, Antsirabe, Madagascar
| | | | - P Bernadin
- HJRA Government Hospital, Antananarivo, Madagascar
| | - BY Chang
- St James's University Hospital, Leeds, UK
| |
Collapse
|
24
|
Razis E, Selviaridis P, Fletcher J, Labropoulos S, Caprioli R, Karkavelas G, Zhu M, Kalebic T, Norris J, Fountzilas G. Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2023] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2023 Background: Glioblastoma multiforme (GBM) carries a grave prognosis. There are phase I-II studies indicating that imatinib is active in GBM in pre-treated patients. To better understand the molecular basis of imatinib’s activity in this disease we performed a pharmacodynamic neoadjuvant study with imatinib in GBM. Methods: Patients underwent CT guided biopsy of their brain tumors. If diagnosed with GBM they were immediately treated with 7 days of imatinib 400mg po BID followed by either definitive surgery or, if that was not feasible, followed by re-biopsy. Corticosteroid dose was stable during this period and valproic acid was the only anti-epileptic drug allowed in order to avoid pharmacokinetic interaction with imatinib. Treatment after recovery was as per usual institutional policy. Pre and post treatment tissue specimens were analyzed by immunohistochemistry, proteomic technology and molecular biological methods. Pharmacokinetic studies were also performed. Results: Twenty patients were enrolled in 2 institutions with a median age of 64, of which 14 were male and 6 female. PS was 0 in 2, 1 in 9 and 2 in 9. Seventeen patients had pure GBM, 2 had mixed GBM with astrocytoma and one had anaplastic astrocytoma. Eighteen patients had stable disease on pre and post treatment MRI, one had progressed and one was not evaluable. Median survival was 6.2 months (1.1–18mo). Intact imatinib was quantified in the post treatment tissue specimens and correlations were made with serum imatinib levels per patient. No correlation was seen. Tissue specimens were analyzed by in situ MALDI mass spectroscopy and differential protein expression profiles were detected, when pre and post treatment specimens were compared. The identification of candidate proteins is ongoing. In 11 patients with evaluable, high-quality, matched pre and post imatinib biopsies, 4 had biochemical evidence of tumor response (decreased AKT or MAPK, or increased p27). In addition, 2 patients showed high-level EGFR activation, and one patient had high-level PDGFR activation. Conclusions: Treatment of GBM patients with imatinib results in measurable levels of the drug in the tumor. Potential indicators of biochemical response in a subset of patients were identified. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Razis
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - P. Selviaridis
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - J. Fletcher
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - S. Labropoulos
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - R. Caprioli
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - G. Karkavelas
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - M. Zhu
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - T. Kalebic
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - J. Norris
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| | - G. Fountzilas
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University, Tennessee, TN; Novartis Oncology, East Hanover, New Jersey, NJ; Protein Discovery Inc. Knoxville, Tennessee, TN
| |
Collapse
|
25
|
|
26
|
|
27
|
Malik R, Krockenberger MB, O'Brien CR, White JD, Foster D, Tisdall PLC, Gunew M, Carr PD, Bodell L, McCowan C, Howe J, Oakley C, Griffin C, Wigney DI, Martin P, Norris J, Hunt G, Mitchell DH, Gilpin C. Nocardia infections in cats: a retrospective multi-institutional study of 17 cases. Aust Vet J 2006; 84:235-45. [PMID: 16879126 DOI: 10.1111/j.1751-0813.2006.00004.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To record 17 cases of nocardiosis in cats from eastern Australia and to compare this series with cases previously reported. DESIGN Retrospective/prospective study. RESULTS Nocardia spp infections were diagnosed in 17 cats over 14 years from the three eastern states of Australia. There were no isolates from dogs during this period, but one isolate from a koala and two from dairy cows. The majority of cats presented with spreading lesions of the subcutis and skin associated with draining sinus tract(s). Early cutaneous lesions consisted of circumscribed abscesses. Infections spread at a variable rate, generally by extension to adjacent tissues. Lesions were generally located in regions subjected to cat bite or scratch injuries, including limbs, body wall, inguinal panniculus and nasal bridge. In some other cases, lesions were situated on distal extremities. The clinical course was variable, from chronic, indolent, initially localised infections to acute fulminating disease. Of the 17 cats, 14 were domestic crossbreds and three were purebreds. There was a preponderance of male cats (12 castrated, 1 entire young adult, 1 entire kitten). Nine of 17 cats were 10 years or older. Interestingly, the majority of infections were attributable to N nova. Immediate and/or predisposing causes could be identified in all cases, and included: renal transplantation [one cat]; chronic corticosteroid administration [three cats]; catabolic state following chylothorax surgery [one cat]; fight injuries [seven cats]; FIV infections [three of seven cats tested]. Of the 17 cats, three were apparently cured. Four were thought to be cured, but infection recurred after several months. Three cats responded partially but were euthanased, while another was improving when it died of unrelated complications. Two died despite treatment and two were euthanased without an attempt at therapy. For two cats there were either insufficient records or the patient was lost to follow up. CONCLUSION Nocardiosis is a rare, serious disease. Currently it is more common in cats than dogs. Nocardial panniculitis may be clinically indistinguishable from the syndrome caused by rapidly growing mycobacteria. Although the prognosis is guarded, patients with localised infections caused by N nova often respond to appropriate therapy. If definitive treatment is delayed because of misdiagnosis, the disease tends to become chronic, extensive and refractory. Insufficient duration of therapy leads to disease recurrence.
Collapse
Affiliation(s)
- R Malik
- Post Graduate Foundation in Veterinary Science, Conference Centre, Building B22, The University of Sydney, New South Wales 2006, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Affiliation(s)
- J H Norris
- The Pathology Department, University of Melbourne
| | | |
Collapse
|
29
|
Keller HH, Hedley MR, Wong SSL, Vanderkooy P, Tindale J, Norris J. Community organized food and nutrition education: participation, attitudes and nutritional risk in seniors. J Nutr Health Aging 2006; 10:15-20. [PMID: 16453053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
UNLABELLED Evergreen Action Nutrition (EAN) is a health promotion program designed to facilitate relatively healthy members of a seniors recreation center to maintain their nutritional health as they age. A main goal of this project was to demonstrate the feasibility and relevance of using the community organization approach to develop a nutrition education program for seniors. METHODS Using the current membership list, seniors were randomly selected to receive a mailed baseline (n=247) questionnaire. A follow-up survey (n=251) was sent out to randomly selected members three years later to determine participation in EAN and reported behavior change. Although not the same individuals, responses were compared to baseline to determine changes in nutritional risk. Items from the Diet and Health Knowledge survey were compared by EAN participation. RESULTS The program had a large reach with 162 survey respondents (64.5%) reporting some level of participation and 51% reporting "frequent" participation. Use of informal forms of education predominated (e.g. displays). Significant differences were found between baseline and follow-up for risk attributed to low intake of fruits and vegetables and frequency of eating, with EAN participants having reduced risk of low fruit and vegetable intake. Those participating in formal education (e.g. food workshops) reported more frequent changes in food practices than those participating in informal activities. EAN participants appear to have more healthy nutrition attitudes/beliefs. CONCLUSION The community organization approach to program planning and delivery leads to the development of diverse and appropriate nutrition education activities for seniors. Informal and formal health promotion activities can be successfully implemented in recreation centers.
Collapse
Affiliation(s)
- H H Keller
- Department of Family Relations and Applied Nutrition, University of Guelph, Guelph, ON Canada N1G 2W1.
| | | | | | | | | | | |
Collapse
|
30
|
Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Tveter TS, Videaek F, Wada R, Yin Z, Zgura IS. Charged meson rapidity distributions in central Au+Au collisions at square root(sNN) = 200 GeV. Phys Rev Lett 2005; 94:162301. [PMID: 15904216 DOI: 10.1103/physrevlett.94.162301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2004] [Indexed: 05/02/2023]
Abstract
We have measured rapidity densities dN/dy of pi+/- and K+/- over a broad rapidity range (-0.1 < y < 3.5) for central Au + Au collisions at square root(sNN) = 200 GeV. These data have significant implications for the chemistry and dynamics of the dense system that is initially created in the collisions. The full phase-space yields are 1660 +/- 15 +/- 133 (pi+), 1683 +/- 16 +/- 135 (pi-), 286 +/- 5 +/- 23 (K+), and 242 +/- 4 +/- 19 (K-). The systematics of the strange to nonstrange meson ratios are found to track the variation of the baryochemical potential with rapidity and energy. Landau-Carruthers hydrodynamics is found to describe the bulk transport of the pions in the longitudinal direction.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Nuclear stopping in Au+Au collisions at square root of S(NN)=200 GeV. Phys Rev Lett 2004; 93:102301. [PMID: 15447397 DOI: 10.1103/physrevlett.93.102301] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2003] [Indexed: 05/24/2023]
Abstract
Transverse momentum spectra and rapidity densities, dN/dy, of protons, antiprotons, and net protons (p-p) from central (0%-5%) Au+Au collisions at square root of S(NN)=200 GeV were measured with the BRAHMS experiment within the rapidity range 0</=y</=3. The proton and antiproton dN/dy decrease from midrapidity to y=3. The net-proton yield is roughly constant for y<1 at dN/dy approximately 7, and increases to dN/dy approximately 12 at y approximately 3. The data show that collisions at this energy exhibit a high degree of transparency and that the linear scaling of rapidity loss with rapidity observed at lower energies is broken. The energy loss per participant nucleon is estimated to be 73+/-6 GeV.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, Blegdamsvej 17, University of Copenhagen, Copenhagen 2100, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Arsene I, Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Lindal S, Lystad G, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Neumann B, Nielsen BS, Norris J, Ouerdane D, Płaneta R, Rami F, Ristea C, Ristea O, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Transverse-momentum spectra in Au+Au and d+Au collisions at sqrt[s(NN)]=200 GeV and the pseudorapidity dependence of high-p(T) suppression. Phys Rev Lett 2003; 91:072305. [PMID: 12935010 DOI: 10.1103/physrevlett.91.072305] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2003] [Indexed: 05/24/2023]
Abstract
We present spectra of charged hadrons from Au+Au and d+Au collisions at sqrt[s(NN)]=200 GeV measured with the BRAHMS experiment at RHIC. The spectra for different collision centralities are compared to spectra from p+(-)p collisions at the same energy scaled by the number of binary collisions. The resulting ratios (nuclear modification factors) for central Au+Au collisions at eta=0 and eta=2.2 evidence a strong suppression in the high p(T) region (>2 GeV/c). In contrast, the d+Au nuclear modification factor (at eta=0) exhibits an enhancement of the high p(T) yields. These measurements indicate a high energy loss of the high p(T) particles in the medium created in the central Au+Au collisions. The lack of suppression in d+Au collisions makes it unlikely that initial state effects can explain the suppression in the central Au+Au collisions.
Collapse
Affiliation(s)
- I Arsene
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bearden IG, Beavis D, Besliu C, Blyakhman Y, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jakobsen E, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Keutgen T, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Olness J, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Wieloch A, Yin Z, Zgura IS. Rapidity dependence of charged antihadron to hadron ratios in Au+Au collisions at sqrt[s(NN)]=200 GeV. Phys Rev Lett 2003; 90:102301. [PMID: 12688991 DOI: 10.1103/physrevlett.90.102301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2002] [Indexed: 05/24/2023]
Abstract
We present ratios of the numbers of charged antihadrons to hadrons (pions, kaons, and protons) in Au+Au collisions at sqrt[s(NN)]=200 GeV as a function of rapidity in the range y=0-3. While the ratios at midrapidity are approaching unity, the K(-)/K(+) and p;/p ratios decrease significantly at forward rapidities. An interpretation of the results within the statistical model indicates a reduction of the baryon chemical potential from mu(B) approximately 130 MeV at y=3 to mu(B) approximately 25 MeV at y=0.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, Blegdamsvej 17, University of Copenhagen, Copenhagen 2100, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Dyer AA, Ashkan K, Norris J. Back pain and systemic compromise. Postgrad Med J 2002; 78:373, 377. [PMID: 12151700 PMCID: PMC1742375 DOI: 10.1136/pmj.78.920.373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- A A Dyer
- Department of Neurosurgery, Hurstwood Park Neurological Centre, Haywards Heath, West Sussex, UK
| | | | | |
Collapse
|
35
|
Bearden IG, Beavis D, Besliu C, Blyakhman Y, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jakobsen E, Jipa A, Jørdre JI, Jundt F, Jørgensen CE, Karabowicz R, Keutgen T, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Olness J, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Thorsteinsen TF, Tveter TS, Videbaek F, Wada R, Wieloch A, Zgura IS. Pseudorapidity distributions of charged particles from Au + Au collisions at the maximum RHIC energy, square root[s(NN)] = 200 GeV. Phys Rev Lett 2002; 88:202301. [PMID: 12005556 DOI: 10.1103/physrevlett.88.202301] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2001] [Revised: 02/14/2002] [Indexed: 05/23/2023]
Abstract
We present charged-particle multiplicities as a function of pseudorapidity and collision centrality for the 197Au+197Au reaction at square root[s(NN)] = 200 GeV. For the 5% most central events we obtain dN(ch)/deta/(eta = 0) = 625+/-55 and N(ch)/(-4.7< or =eta < or =4.7) = 4630 +/- 370, i.e., 14% and 21% increases, respectively, relative to square root[s(NN)] = 130 GeV collisions. Charged-particle production per pair of participant nucleons is found to increase from peripheral to central collisions around midrapidity. These results constrain current models of particle production at the highest RHIC energy.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Angerhofer A, Toporowicz M, Bowman M, Norris J, Levanon H. Effect of triplet spin dynamics memory in electron-transfer reaction. Fourier transform-electron paramagnetic resonance spectroscopy. ACTA ACUST UNITED AC 2002. [DOI: 10.1021/j100337a002] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Creighton S, Hwang JK, Warshel A, Parson WW, Norris J. Simulating the dynamics of the primary charge separation process in bacterial photosynthesis. Biochemistry 2002. [DOI: 10.1021/bi00402a043] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
|
39
|
Harwood J, Ground M, Buttner A, Gustafson DT, Hinchey MA, White B, Wydeven MS, Norris J. Clarifying language in a new curriculum. Nurse Educ 2001; 26:253-5. [PMID: 12141635 DOI: 10.1097/00006223-200111000-00005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- J Harwood
- Creighton University School of Nursing, Omaha, NE 68178, USA
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Norris J. The country doctor in British Columbia: 1887-1975. B C Stud 2001:15-39. [PMID: 11631744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
41
|
Clark ST, Hackman G, Janssens RV, Clark RM, Fallon P, Floor SN, Lane GJ, Macchiavelli AO, Norris J, Sanders SJ, Svensson CE. Empirical investigation of extreme single-particle behavior of nuclear quadrupole moments in highly collective A approximately 150 superdeformed bands. Phys Rev Lett 2001; 87:172503. [PMID: 11690269 DOI: 10.1103/physrevlett.87.172503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2001] [Indexed: 05/23/2023]
Abstract
The intrinsic quadrupole moment Q(0) of superdeformed rotational bands in A approximately 150 nuclei depends on the associated single-particle configuration. We have derived an empirical formula based on the additivity of effective quadrupole moments of single-particle orbitals that describes existing measurements from (142)Sm to (152)Dy. To further test the formula, the predicted Q(0) moments for two superdeformed bands in (146)Gd of 14.05 eb were confronted with a new measurement yielding 13.9+/-0.4 eb and 13.9+/-0.3 eb, respectively. This excellent agreement provides empirical evidence of extreme single-particle behavior in highly deformed, collective systems.
Collapse
Affiliation(s)
- S T Clark
- Department of Physics and Astronomy, University of Kansas, Lawrence, Kansas 66045, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kraus WE, Torgan CE, Duscha BD, Norris J, Brown SA, Cobb FR, Bales CW, Annex BH, Samsa GP, Houmard JA, Slentz CA. Studies of a targeted risk reduction intervention through defined exercise (STRRIDE). Med Sci Sports Exerc 2001; 33:1774-84. [PMID: 11581566 DOI: 10.1097/00005768-200110000-00025] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE The Studies of a Targeted Risk Reduction Intervention through Defined Exercise (STRRIDE) trial is a randomized controlled clinical trial designed to study the effects of exercise training regimens differing in dose (kcal.wk-1) and/or intensity (relative to peak VO2) on established cardiovascular risk factors and to investigate the peripheral biologic mechanisms through which chronic physical activity alters carbohydrate and lipid metabolism to result in improvements in these parameters of cardiovascular risk in humans. METHODS We will recruit 384 subjects and randomly assign them to one of three exercise training regimens or to a sedentary control group. The recruiting goal is to attain a subject population that is 50% female and 30% ethnic minority. The overall strategy is to use graded exercise training regimens in moderately overweight subjects with impairments in insulin action and mild to moderate lipid abnormalities to investigate whether there are dose or intensity effects and whether adaptations in skeletal muscle (fiber type, metabolic capacity, and/or capillary surface area) account for improvements in insulin action and parameters of lipoprotein metabolism. We will study these variables before and after exercise training, and over the course of a 2-wk detraining period. The study sample size is chosen to power the study to examine differences in responses between subjects of different gender and ethnicity to exercise training with respect to the least sensitive parameter-skeletal muscle capillary density. RESULTS The driving hypothesis is that improvements in cardiovascular risk parameters derived from habitual exercise are primarily mediated through adaptations occurring in skeletal muscle. CONCLUSION Identification that amount and intensity of exercise matter for achieving general and specific health benefits and a better understanding of the peripheral mechanisms mediating the responses in carbohydrate and lipid metabolism to chronic physical activity will lead to better informed recommendations for those undertaking an exercise program to improve cardiovascular risk.
Collapse
Affiliation(s)
- W E Kraus
- Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lamah M, Norris J, Caffarey SM, Broughton M, Marks CG. Effect of faecal occult blood testing on colorectal cancer mortality in the surveillance of subjects at moderate risk of colorectal neoplasia: a case-control study. Int J Colorectal Dis 2001; 16:313-7. [PMID: 11686530 DOI: 10.1007/s003840100316] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Colonoscopy is the established method of surveillance of subjects at high risk of developing colorectal neoplasia. Its role in the surveillance of a population at moderate risk is less clear, however, as the procedure is expensive, time consuming and occasionally hazardous. The aim of this study was to estimate by case-control methods the effect of faecal occult blood (FOB) screening on colorectal cancer (CRC) mortality in a population at moderate risk of developing CRC. Screening by FOB testing prior to diagnosis in patients over the age of 45 years who died of CRC diagnosed in 1989-1998 was compared with screening in controls matched with the case for age and sex. Information about episodes of FOB testing and potential confounders was obtained from the data collection system of the screening programme. Cases were less likely than controls to have ever been screened, with an odds ratio of 0.64 (95% confidence interval 0.34-1.15) for exposure to at least one FOB testing. There was no significant difference between the sub-groups according to gender, age at diagnosis or location of the cancer. The inverse association between screening for faecal occult blood and fatal colorectal cancer suggests that screening in a population at moderate risk of CRC can reduce mortality from CRC in this group.
Collapse
Affiliation(s)
- M Lamah
- Royal Surrey County Hospital, Surrey, UK.
| | | | | | | | | |
Collapse
|
44
|
Rowan DD, Hunt MB, Fielder S, Norris J, Sherburn MS. Conjugated triene oxidation products of alpha-farnesene induce symptoms of superficial scald on stored apples. J Agric Food Chem 2001; 49:2780-7. [PMID: 11409966 DOI: 10.1021/jf0015221] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
The sesquiterpene alpha-farnesene (1) and its conjugated triene oxidation products accumulate in the skin of apples after harvest and are implicated as the causal agents of superficial scald. Conjugated triene oxidation products and analogues were synthesized and applied to the surface of Granny Smith apples either as vapors or in squalane. Farnesyl hydroperoxide (2a), trienol (2b), endoperoxide (3a), dehydronerolidol (5), and cumyl hydroperoxide (4) all produced the symptoms of superficial scald when applied at nanomolar doses. Scald-inducing activity was dependent on the mode of application. Farnesyl hydroperoxide (2a) was the most active conjugated triene when applied directly to the apple skin. Trienol (2b) also induced scald symptoms and partially reversed the inhibition of scald caused by diphenylamine.
Collapse
Affiliation(s)
- D D Rowan
- Horticulture and Food Research Institute of New Zealand Ltd., Private Bag 11030, Palmerston North, New Zealand.
| | | | | | | | | |
Collapse
|
45
|
Affiliation(s)
- E Hadjihannas
- Department of Neurosurgery, Hurtswood Park Neurological Centre, Haywards Heath, West Sussex RH16 4EX, UK
| | | | | |
Collapse
|
46
|
Abstract
Following a curriculum revision, which emphasized critical thinking, a school of nursing selected the California Critical Thinking Skills Test (CCTST) as a standardized outcomes measure for its bachelor's of science in nursing (BSN) program. Students in three tracks of the program were administered the CCTST on entry into the nursing curriculum and again on exit. Paired t tests for dependent samples were used to analyze pretest-posttest differences of all students (N = 136) in the program. Results for students in each of the three tracks demonstrated significantly improved (P < or = .05) CCTST scores on all subscales and total scores, with one exception. RN to BSN students' scores on the Analysis subscale approached but did not reach significance (P = .058). Implications for evaluation are discussed.
Collapse
Affiliation(s)
- S S Spelic
- Creighton University School of Nursing, Omaha, Nebraska, USA
| | | | | | | | | | | |
Collapse
|
47
|
Swift B, Lauder I, Black S, Norris J. An estimation of the post-mortem interval in human skeletal remains: a radionuclide and trace element approach. Forensic Sci Int 2001; 117:73-87. [PMID: 11230949 DOI: 10.1016/s0379-0738(00)00451-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Estimation of the post-mortem interval remains a contentious issue, with forensic pathologists often relying upon the recognition of morphological changes.A radionuclide approach has often been suggested in the literature, although limitations have prevented its application, most notably those of diagenesis. Within this pilot study, we show for the first time that there is a correlation between certain radionuclide content and time since death.A larger study is proposed to confirm these findings and possibly provide a calibration against which bones uncovered can be dated.
Collapse
Affiliation(s)
- B Swift
- Department of Pathology, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, LE2 7LX, Leicester, UK.
| | | | | | | |
Collapse
|
48
|
Rubinchik S, Lowe S, Jia Z, Norris J, Dong J. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters. Gene Ther 2001; 8:247-53. [PMID: 11313797 DOI: 10.1038/sj.gt.3301364] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2000] [Accepted: 10/18/2000] [Indexed: 11/09/2022]
Abstract
Tissue-specific transgene expression is a valuable research tool and is of great importance in delivering toxic gene products with adenovirus vectors to tumors. Limiting cytotoxic gene expression to the target cells is highly desirable. While a number of successful applications of tissue- and tumor-specific gene expression using Ad vectors has been reported, cloning of some promoters into Ad vectors resulted in modulation or loss of tissue specificity. This phenomenon is likely the result of the interaction of E1A enhancer (and possibly other Ad sequences) with the promoter cloned in the E1 region. We have compared performance parameters of prostate-specific and tet-regulatable promoters in plasmids containing the terminal repeat sequences of Ad5 with or without the E1A enhancer. Subsequently, adenoviral vectors were constructed containing identical expression units either in the E1 region or near the right ITR, and tested in several cell lines. Here, we report that promoters placed near the right ITR of Ad5 retain higher selectivity and lower background expression in both plasmid and adenovirus vectors. We confirm that the E1A enhancer can interfere with the desired activity of nearby promoters, and describe an alternative transgene insertion site for construction of Ad vectors.
Collapse
Affiliation(s)
- S Rubinchik
- Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425-2230, USA
| | | | | | | | | |
Collapse
|
49
|
Brand RM, Hannah TL, Norris J, Iversen PL. Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev 2001; 11:1-6. [PMID: 11258617 DOI: 10.1089/108729001750072074] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The potential for using antisense compounds as therapeutic agents has generated great enthusiasm. Strategies for delivery of these compounds are, therefore, of great interest. Transdermal iontophoresis has been used successfully as an enhancement technique for the transdermal delivery of these compounds in vitro. The effectiveness of using percutaneous penetration as a means to deliver therapeutic levels of these compounds in vivo, however, remains to be demonstrated. The purpose of this work was to demonstrate the ability of iontophoretically delivered compounds to alter enzyme levels in the intact rat. A C5 propyne-modified phosphorothioate oligonucleotide (PS-ODN) targeted to the cytochrome p450-3A2 (CYP3A2) mRNA translational start site and the reverse sequence, used as a control, were synthesized. A patch containing either an oligonucleotide or a buffer control was placed on the animal's back, and an iontophoretic current of 0.5 mA/cm2 was applied for 3.5 hours. Twenty-four hours later, CYP3A2 levels were measured noninvasively using the midazolam-induced sleeping rat model. Liver and small intestinal microsomes were made after completion of sleep studies and assayed for CYP3A2, CYP1A1/2, CYP2B1/2, and CYP2E1. Midozolam-treated animals with antisense to CYP3A2 slept significantly longer than did the controls (p < 0.05). CYP3A2 levels were significantly lower in liver microsomes from antisense-treated animals than in either buffer control (p < 0.001) or reverse sequence animals (p < 0.05). The reverse sequence was also significantly different from the buffer control (p < 0.01), indicating a nonspecific effect of the PS background. Nontarget cytochrome levels were not altered by treatment. There were no significant differences in small intestine CYP3A2 levels between treatment groups. These data demonstrate that transdermally delivered PS-ODN can reach concentrations sufficient to induce changes in specific target enzymes in vivo. Further studies are warranted to investigate potential uses for these molecules.
Collapse
Affiliation(s)
- R M Brand
- Department of Biological Systems Engineering. University of Nebraska, Lincoln 68583-0726, USA
| | | | | | | |
Collapse
|
50
|
Abstract
The objective of this study is to examine the applicability of process reengineering in a healthcare operational environment. The intake process of a mental healthcare service delivery system is analyzed systematically to identify process-related problems. A methodology which utilizes an open system orientation coupled with process reengineering is utilized to overcome operational and patient related problems associated with the pre-reengineered intake process. The systematic redesign of the intake process resulted in performance improvements in terms of cost, quality, service and timing.
Collapse
Affiliation(s)
- A J Czuchry
- East Tennessee State University, Johnson City 37614-0552, USA.
| | | | | |
Collapse
|